HeinOnline is a subscription-based resource containing thousands of academic and legal journals from inception; complete coverage of government documents such as U.S. Statutes at Large, U.S. Code, Federal Register, Code of Federal Regulations, U.S. Reports, and much more. Documents are image-based, fully searchable PDFs with the authority of print combined with the accessibility of a user-friendly and powerful database. For more information, request a quote or trial for your organization below.
![handle is hein.congrecreports/crptxacim0001 and id is 1 raw text is: AUTHENTICATE
U.S. GOVERNMENT
INFORMATION
GPO
116TH CONGRESS 1.1REPT. 116 52
1st Session HOUSE OF REPRESENTATIVES Part 1
PROTECTING CONSUMER ACCESS TO GENERIC DRUGS
ACT OF 2019
MAY 10, 2019.-Committed to the Committee of the Whole House on the State of
the Union and ordered to be printed
Mr. PALLONE, from the Committee on Energy and Commerce,
submitted the following
REPORT
[To accompany H.R. 1499]
[Including cost estimate of the Congressional Budget Office]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 1499) to prohibit brand name drug manufacturers
from compensating generic drug manufacturers to delay the entry
of a generic drug into the market, and to prohibit biological product
manufacturers from compensating biosimilar and interchangeable
product manufacturers to delay entry of biosimilar and inter-
changeable products, and for other purposes, having considered the
same, report favorably thereon with an amendment and rec-
ommend that the bill as amended do pass.
CONTENTS
Page
Purpose and Sum m ary ........................................................................................... 6
Background and Need for the Legislation ............................................................. 6
Com m ittee H earings ................................................................................................ 7
Com m ittee Consideration ........................................................................................ 8
C om m ittee V otes ...................................................................................................... 8
Oversight Findings ................................................................................................. 8
New Budget Authority, Entitlement Authority, and Tax Expenditures ............. 8
Congressional Budget Office Estimate ................................................................... 8
Federal M andates Statem ent ................................................................................. 12
Statement of General Performance Goals and Objectives .................................... 12
Duplication of Federal Program s ............................................................................ 12
Com m ittee Cost Estim ate ....................................................................................... 12
Earmarks, Limited Tax Benefits, and Limited Tariff Benefits ........................... 12
Advisory Com m ittee Statem ent .............................................................................. 12
Applicability to Legislative Branch ........................................................................ 12
Section-by-Section Analysis of the Legislation ...................................................... 13
Changes in Existing Law Made by the Bill, as Reported ..................................... 15
89-006](ViewImageLocal?handle=hein.congrecreports/crptxacim0001&div=1&collection=&method=preview&ext=.png&size=3)